Dr. Danielle Orozco Cosio has joined the TimeWarp Science Advisory Board

We are excited to welcome Dr. Danielle Orozco Cosio to the TimeWarp Labs Scientific Advisory Board.

Danielle is a neuroscientist, entrepreneur, and cross-disciplinary leader whose career has spanned molecular biology, neuroscience, clinical research, and healthcare delivery. She brings a perspective that is especially important to what we are building at TimeWarp: understanding not only whether an intervention is scientifically compelling, but how that science ultimately reaches and works for a real person.

Danielle earned her undergraduate degree in Molecular Biology from MIT before completing her PhD in Neuroscience at MIT. Earlier in her career, she worked in clinical research at Massachusetts General Hospital, contributing to Alzheimer's-related neuroimaging studies and gaining firsthand experience with the translation of complex biological research into human clinical settings.

Today, she leads GTM and Customer Success at MyDose AI, a telehealth infrastructure provider focused on enabling healthcare organizations to deliver care at scale. Her work sits at the intersection of science, technology, healthcare operations, and the patient experience.

From good science to something people can actually use

Longevity is often discussed as a search for the right molecule, pathway, or biological target. Those questions matter enormously, and they have shaped the development of Protocol 01 from the beginning.

But identifying promising biology is only part of the challenge.

An intervention has little value if it is too complicated to follow consistently. A sophisticated formulation still has to fit into someone's morning routine. A protocol designed for years of use has to remain understandable and sustainable long after the novelty disappears.

That makes adherence, delivery, and real-world usability part of the scientific problem itself.

Danielle has spent her career working across both sides of that equation. Her scientific training allows her to evaluate the biology, while her experience in clinical research and healthcare infrastructure provides a deeper understanding of what happens when that science leaves the laboratory and reaches the patient.

That combination is particularly relevant to TimeWarp.

Engineering for sustained use

Protocol 01 was designed as a systems-level longevity protocol targeting the 12 Hallmarks of Aging, but the ambition has never been simply to fit more science into a bottle.

We are trying to build a protocol people can realistically integrate into their lives and remain on over long periods of time.

That means thinking about formulation, dosing, routine design, communication, behavior, and experience as parts of the same system.

Danielle's perspective strengthens that work. She helps us challenge assumptions about how scientific complexity should be translated, where friction can emerge, and how we can make sophisticated longevity science more usable without oversimplifying the biology behind it.

As TimeWarp moves from years of formulation and development into commercialization, that perspective becomes increasingly valuable.

We are delighted to have Danielle joining our Scientific Advisory Board and helping us build longevity infrastructure designed not just for compelling science, but for sustained real-world use.

Welcome to TimeWarp, Danielle.

Protocol 01 opens soon.
Join the waitlist at timewarp.com.